J&J Cuts Drug Discovery Timelines in Half with AI
Screening chemical compounds and biologics for new drug candidates used to take months; it now runs twice as fast. Regulatory paperwork is getting the same speed boost, which matters just as much as the discovery work itself in an industry where filings are often the real bottleneck.
practitioners › Confirmed by Johnson & Johnson's CIO on April 27, 2026: a 2x speedup in lead generation, though no details were given on which model is behind it.
www.reuters.com →